健世科技作为国产医疗新势力,在全球结构性心脏病微创治疗领域迅速崛起,凭借197项全球已授权专利,成为首个将TTVR研究写入欧洲心脏病学会指南的中国企业。2024年财务状况逐步稳固,亏损收窄52.2%,账面货币资金达7.08亿元,为2025年的“商业化元年”奠定了基础。公司核心产品LuX-Valve Plus和Ken-Valve在全球和本土市场上发挥重要作用。LuX-Valve Plus是全球首款...
Source Link健世科技作为国产医疗新势力,在全球结构性心脏病微创治疗领域迅速崛起,凭借197项全球已授权专利,成为首个将TTVR研究写入欧洲心脏病学会指南的中国企业。2024年财务状况逐步稳固,亏损收窄52.2%,账面货币资金达7.08亿元,为2025年的“商业化元年”奠定了基础。公司核心产品LuX-Valve Plus和Ken-Valve在全球和本土市场上发挥重要作用。LuX-Valve Plus是全球首款...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.